On March 18, 2026, MiniMed Group, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its MiniMed Flex™, a next-generation discreet, smartphone-controlled insulin pump. This approval comes several months earlier than anticipated, allowing for an expedited commercialization process for this innovative product. The MiniMed Flex is designed to enhance the management of diabetes through advanced technology, providing users with greater control over their insulin delivery. The development of the MiniMed Flex was partially funded by affiliates of Blackstone Life Sciences Advisors L.L.C. Under the terms of the research and development agreement, Blackstone will receive either a mid-to-high single-digit royalty on net sales or a minimum payment of $157 million over the first two years following the product's regulatory approval and commercial launch. MiniMed anticipates recognizing a one-time charge of $157 million in the fourth quarter of fiscal year 2026 related to this agreement. The FDA clearance is expected to significantly impact MiniMed's financial outlook, as the company prepares for the product's market introduction. This development is seen as a positive step for MiniMed, potentially leading to increased revenue and market share in the diabetes management sector. The company is poised to leverage this approval to enhance its competitive position and drive growth in the coming years.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.